Patients taking the first-of-a-kind pill, called daraxonrasib, lived for a median of 13.2 months compared with 6.7 months for chemotherapy recipients, studies showed.

Original source: https://www.cbsnews.com/news/fda-approves-pancreatic-cancer-drug-daraxonrasib-could-extend-patients-lives/